

## DAFTAR PUSTAKA

1. Lesmana CR, Hasan I, Gani RA, Sanityoso A, Setiawan PB, Djumhana A. Konsensus nasional penatalaksanaan hepatitis B di Indonesia 2017.editor : Lesmana C R. PPHI. Jakarta;2017:1—82.
2. Tedjha MD. Genetic diversity of hepatitis B virus in Indonesia : epidemiological and clinical significance. Thesis. Utrecht University; 2012.
3. Arnelis , Julius , Zubir N, Miro S, Siburian M. Distribution of hepatitis B virus ( HBV) genotype among different ethnics hospitalized in M. Djamil Hospital, Padang (Continued study) dalam naskah lengkap Konas XIV PGI. In PEGI, PIN; 2009; Bali.
4. Julius , Thedja M, Arnelis , Miro , Zubir. Distribution of serotype and genotype in West Sumatera revisiting adr-zone in West Indonesia. Hepatol Int. 2008; 2: c20.
5. Lamontagne R, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016; 2:163—86.
6. Seeger C, Mason Ws. Molecular biology of hepatitis B virus infection. Virology. 2015; 0:672—86.
7. Zentella MLC , Munoz RH. Is Liver enzyme release really associated with cell necrosis induced by oxidant stress? Oxid med and cell longev. 2016;2016:1—12.
8. Kasarala G, Tillmann HL. Standard liver tests. Clin Liver Dis. 2016; 8(1): 13—18.
9. Giannini E, Testa R, Savarino V. Liver enzyme alteration : a guide for clinicians. CMAJ. 2005; 172(3):367—78.

10. Ozkara , Tosun , Sari , Kilic G, Akera V, Sezikli , et al. The correlation of serum transaminase values with fibrosis staging and necroinflammatory activity. *Turkiye Klinikleri J Med Sci.* 2011; 31(1):68—74.
11. Demir NA, Kolgelier SK, Ozcimen , Gungor G, Sumer , Inkaya C, et al. Evaluation of the relation between hepatic fibrosis and basic laboratory parameters in patients with chronic hepatitis B fibrosis and basic laboratory parameters. *Hepat Mon.* 2014; 14(4): 1—5
12. Dayan S . Dal T, Tekin R, Deveci O, Ipek D, Ozcan N, et al. Non-invasive parameters in the assessment of liver fibrosis. *Biomed Res.* 2017; 28(5):2180—84.
13. Kirisci O, Paksoy T, Caliskan A, Analan A, Ozkaya E, Kirmaci , et al. The relationship between serum DNA levels and serological markers, ALT and AST with liver histology in chronic hepatitis B patients. *Acta Med Mediterranea.* 2016; 32:1805—12.
14. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. *J Gen Virol.* 2006; 87(6):1439—49.
15. Abbas AK. Immunologic tolerance and autoimmunity. In *Cellular And Molecular Immunology* Philadelphia: Elsevier; 2015.
16. Bratawidjaja , Rengganis. Imunologi virus in Imunologi Dasar. 8th ed. Jakarta: Balai Penerbit FKUI; 2009;312—18
17. Chang KM. Hepatitis B immunology for clinicians. *Clin Liver Dis.* 2010; 14(3):409—24.
18. Fallatah H. Noninvasive Biomarkers of liver fibrosis: an overview. *Advances in Hepatology;*2014:1—15.
19. Jieanu C, Ungureanu B, Sandulescu D, Gheonea A, Tudorascu D, Ciurea M, et al. Quantification of liver fibrosis in chronic hepatitis B virus infection. *J Med Life.* 2015; 8(3):285—90.

20. Wilder J, Patel K. The Clinical utility of fibroscan as noninvasive diagnostic test for liver disease. *Med Devices: Evidence and Research*. 2014; 7:107—14.
21. Parikh P, Ryan J, Tsochatzis E. Fibrosis assesment in patient with chronic hepatitis B virus (HBV) infection. *Ann Transl Med*. 2017; 5(3):1—14.
22. Chon YE, Choi EH, Song KJ, Park JY, Han KH, Chon CY et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic Hepatitis B: a meta-Analysis. *PLOS ONE*. 2012;7(9):1—7.
23. Shen C, Yan WZ, Zhao CY, Che HH, Liu XY, Liu ZZ, et al. Increased CD4+CD25+ regulatory T cells correlate with poor short-term outcomes in Hepatitis B virus-related acute-On-chronic liver failure patients. *J Microbiol Immunol Infect*. 2015; 48(2):137—46.
24. Stoop JN, Molen RG, Baan CC, Laan RJ, Kuipers RJ, Kusters JG, et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. *Hepatology*. 2005; 41(4):771—78.
25. Trehanpati N, Vyas AK. Immune regulation by T regulatory cells in hepatitis B virus-related inflammation and cancer. *Scand J Immunol*. 2017; 85(3): 175—81.
26. Langhans B, Krämer B, Louis M, Nischalke HD, Hüneburg R, Staratschek-Jox A, et al. Intrahepatic IL-8 producing Foxp3<sup>+</sup>CD4<sup>+</sup> regulatory T cells and fibrogenesis in chronic hepatitis C. *J Hepatol*. 2013;59(2):229—35.
27. LI X, Xu Y, Hua X, Xi C, Liu J, Huang Y, et al. Levels of hepatic Th17 cells and regulatory T cells upregulated by hepatic stellate cells in advanced HBV-related liver fibrosis. *Journal of Translational Medicine*. 2017; 15(75):1—11.
28. Zhai S, Zhang L, Dang S, Yu Y, Zhao Z, Zhao W et al. The Ratio of Th-17 to Treg cells is associated with survival of patients with acute-on-chronic hepatitis B liver failure. *Viral Immunology*. 2011; 24(4):303—09.
29. Yu X, Guo R, Ming D, Su M, Lin C, Deng Y et al. Ratios of regulatory T cells/T-helper 17 cells and transforming growth factor-β1/interleukin-17 to

- be associated with the development of hepatitis B virus-associated liver cirrhosis. *J Gastroenterol Hepatol.* 2014; 29(5):1065—72
30. Wang F, Jing X, Li G, Wang T, Yang B, Zhu Z, et al. Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma. *Liver Int.* 2012;32(4):644—55.
  31. Charles A, JR Paul T, Mark W. The components of the immune system. In *Immunobiology: The Immune System in Health and Disease.* 5th ed. New York: Garland Science; 2001:1—20
  32. Chang J, Lewin S. Immunopathogenesis of hepatitis B virus infection. *Immunology and Cell Biology.* 2007; 85:16—23.
  33. Balsamova I, Yushchuk N, Mynbaev O, Alla N, Malova E, Shi Z, et al. Immunopathogenesis of chronic hepatitis B. *World Journal Gastroenterology.* 2014; 20(39):14156—71.
  34. Setiati S, Alwi I. Hepatitis B kronik. Dalam Buku Ajar Ilmu Penyakit Dalam. Jakarta Pusat: Interna Publishing. 2016:163—17.
  35. Ma Y, He M, Han J, Yang L, Ji X. A clinical study of HBsAg-activated dendritic cells and cytokine-induced killer cells during the treatment for chronic hepatitis B. *Scand J Immunol.* 2013; 78:387—93.
  36. Liu Q, Zhang Z, Yao J, Shi M, Zhang H, Mao Y, et al. Identification of circulating plasmacytoid dendritic cells in chronic HBV-infected patients. *Zhonghua Ganzangbing Zazhi.* 2006; 14:725—28.
  37. Yaozhong D, Jiangnan X, Jonathan S, Bromberg. T regulatory cell migration during an immune response. *Trends Immunol.* 2012; 33(4):174—180.
  38. Li Jing, Shuang-Jian Q, Wei-Ming, Fu-Ping W, Hong G, Lei L,et al. Significance of the Balance between Regulatory T (Treg) and T Helper 17 (Th17) Cells during Hepatitis B Virus Related Liver Fibrosis. *PLoS One.* 2012; 7(6): 1—13

39. Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. *Virology*. 2015;672—86.
40. Trepo C, chan H, Lok A. Hepatitis B virus infection. *Lancet*. 2014; 384: 2053—61.
41. WHO. New hepatitis data highlight news for urgent global response.2017.
42. Paul K, Stanley M, Joseph KL. ACG practice guideline: evaluation of abnormal liver chemistries. *Am J Gastroenterol* advance online publication. 2016; 112(1):18—35.
43. Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? *Liver InternationaL*. 2014; 34(1):91—96.
44. Kim W, Flamm S, Adrian M, Bodenheimer H. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. *HEPATOLOGY*. 2008; 47(4):1363—70.
45. Shimon S, Dario V, Alexander Y, Rudensky , Rachel E, Niec , et al. The plasticity and stability of regulatory T cells. *Nature Reviews Immunology*. 2013; 13:461—67.
46. Campbel D, Koch A. Phenotypical and fuctional specialization of FOXP3 regulatory cell. *Nat Rev Immunol*. 2011; 11(2):119—30.
47. Feng L, Kang H, Liu L, Cao Y. CD4+CD25+Foxp3+ regulatory T cells contribute in liver fibrosis improvement with interferon alpha. *Inflammation*. 2013; 36(6):1374—82.
48. Stroos L, Gunter J. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute, experimental hepatitis B virus infection. *Hepatology*. 2012; 56:873—83.
49. Zhang CY, Yuan WG, He P, Hui. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. *World J Gastroenterol*. 2016; 22(48):10512—22.

50. Mallat A, Lotersztajn S. Cellular mechanisms of tissue fibrosis. 5. novel insights into liver fibrosis: Mechanism of liver fibrosis. American Journal of Physiology - Cell Physiology. 2013; 305(8):789—99.
51. Zhu C, Li W, LI Y, Gao R. Serum levels of tissue inhibitor of metalloproteinase-1 are correlated with liver fibrosis in patients with chronic hepatitis B. J.Dig.Dis. 2012; 13(11):558—63
52. Gressner R, Weiskirchen R.. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF- $\beta$  as major players and therapeutic targets. J. Cell. Mol. Med. 2006; 10(1): 76—99.
53. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167—85
54. Asselah T, Marcellin P, Bedossa P. Improving performance of liver biopsy in fibrosis assessment. Journal of Hepatology. 2014; 61:193—95.
55. Shiha G, Ibrahim A, Helmy , Kumar S. APASL consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. Hepatol Int. 2017; 11(1):1—30.
56. Adebajo CO, Talwalkar JA, Poterucha JJ, Kim WR, Charlton MR. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl. 2012;18:323—331.
57. Jia J, Hou J, Ding H, Chen G. Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B. 2015; 30(4):756—62.
58. El Hariri , Megid A, Ali T, Hassany M. Diagnostic value of transient elastography (Fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy. 2017; 48(2):329—52.

59. Friedrich R, Ong M, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology*. 2008; 134:960—74.
60. Bisset L, Lung T, Kaelin M, Ludwig E, Dubs R. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. *European Journal Of Haematology*. 2004; 72(3):203—12.
61. Lemoine , Shimawaka , Nayagam S, Khalil M, Suso P, Lloyd J, et al. The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa. *Gut*. 2016; 65(8):1369—76.
62. Kolou M, Katawa G, Salou , Gozo-Akakpo K, Dossim S, Kwarteng , et al. High Prevalence of Hepatitis B Virus Infection in the Age Range of 20-39 Years Old Individuals in Lome. *Open Virol J*. 2017; 11:1—7.
63. Eminler T, Ayyildiz T, Irak K, Kiyici M, Gurel S, Dolarc , et al. AST/ALT ratio is not useful in predicting the degree of fibrosis in chronic viral hepatitis patients. *European Journal of Gastroenterology & Hepatology*. 2015; 27(12):1361—6
64. Abdo AA, Bzeizi KI , Babatin MA, Alshohaibani, Almana H, Alsaad KO, et al. Predictors of significant fibrosis in chronic hepatitis B patients with low viremia. *J Clin Gastroenterol*. 2014; 48(6): 50—6.
65. Tan Y, Ye Y, Zhou X, Chen I, Wen D. Age as a Predictor of significant fibrosis features in HBeAg-negative chronic Hepatitis B virus infection with persistently normal alanine aminotransferase. *PLoS ONE*. 2015; 10(4): 1—16
66. McPherson S, Hardy T, Dufour JF, Petta S, Romero GM, Allison M et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. *Am J Gastroenterol*. 2017; 112(5):740—51

67. Khan F, Shams S, Qureshi ID, Israr , Khan H, Sarwar M, et al. Hepatitis B virus infection among different sex and age groups in Pakistani Punjab. *Virol J.* 2011; 8(225):1—5.
68. Awan Z, Idrees , Amin , Amin I, Butt S, Afzal S, et al. Pattern and molecular epidemiology of Hepatitis B virus genotypes circulating in Pakistan. *Infection, Genetics and Evolution.* 2010; 10:12—46.
69. Wang SH, Chen PJ, Yeh SH. Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. *Journal of Gastroenterology and Hepatology.* 2015; 30:1237—45
70. Sirinawasatien A, Techasirioangkun T. Prevalence determinants of significant liver fibrosis by vibration-controlled transient elastography in Thai chronic Hepatitis B patients.. *Int J Hepatol.* 2018;2018:1—7
71. Montella M, D’Arena G, Crispo A, Capunzo M, Nocerino F, Grimaldi M, et al. Role of sex hormones in the development and progression of Hepatitis B virus-associated hepatocellular carcinoma. *International Journal of Endocrinology.* 2015;2015:1—10.
72. Chen C, Yang H. Natural history of chronic hepatitis B REVEALed. *J Gastroenterol Hepato.* 2011; 26(4): 628—38.
73. Yen Y, Ming c, Tsai M, Tseng P, Lin M, Wu C, et al. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. *Journal of the Formosan Med Association.* 2018; 117(4):268—75
74. Lin CY, Tsai MC, Huang CT, Hsu CW, Tseng SC, Tsai IF, et al. Liver injury is associated with enhanced regulatory T-cell activity in patients with chronic hepatitis B. *Journal of Viral Hep.* 2007;14:503—11
75. Su Z-J, Yu X-P, Guo R.-Y, Ming D-S, Huang L.-Y, Su M.-L et al. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B. *Diagnostic Microbiology and Infect Dis,* 76(4), 437—44

76. Li Q, Zhou Y, Huang CH, Li W. A novel diagnostic algorithm to predict significant liver infflammation in chronic hepatitis B virus infection patients with detectable HBV DNA and persistently normal alanine transaminase. *Scientific Reports*. 2018; 8: 1—7.
77. Aleem A, Rahmat A. Evaluation of CD4+CD25+ regulatory T cells in patients with hepatocellular carcinoma and liver cirrhosis. *The Egyptian Journal of Hospital Medicine*. 2011; 43:182—91.

